Connect with us

Technology

HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Dr. Jonathan Javitt and Dr. David Feifel to Present Keynote Address, Beyond Ketamine Monotherapy: Combined Interventional Treatment of Suicidal Depression and PTSD, at the 8th Annual Neuroscience Innovation Forum in San Francisco

Published

on

The Keynote Address, entitled “Beyond Ketamine: Combined Interventional Treatment of Suicidal Depression and PTSD,” will be presented at 10:30AM PT on Sunday January 12th, 2025Prof. David Feifel MD PHD, designated Chief Medical Innovation Officer of HOPE and Founder of the Kadima Neuropsychiatry Institute, is an international thought leader in the interventional psychiatry spaceNRx Pharmaceuticals recently initiated filing of its NDA for NRX-100 (IV ketamine) for the treatment of suicidal depression Recent announcement of Kadima Neuropsychiatry Institute and Dura Medical as planned cornerstone acquisitions for HOPE Therapeutic’s international network of interventional psychiatry clinics $27 Million in anticipated funding for HOPE Clinic acquisitions and pharmaceutical operations under a binding Term Sheet with an Institutional Investor

MIAMI, Jan. 7, 2025 /PRNewswire/ — HOPE Therapeutics™, Inc., (“HOPE”), a medical and technology driven company and wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (“NRx”, and collectively with HOPE, the “Company”) (Nasdaq:NRXP), today announced that Jonathan Javitt MD MPH, Founder and CEO of NRx and Co-CEO of HOPE, and Prof. David Feifel MD PHD, designated Chief Medical Innovation Officer of HOPE and Founder of the Kadima Neuropsychiatry Institute, will present the Keynote Address at the 8th Annual Neuroscience Innovation Forum on January 12, 2025, at the Marines’ Memorial Club in San Francisco at 10:30am PT. They will also be available for one-on-one meetings with investors and partners at this meeting and the JPM healthcare conference (see contact information below to request a meeting).

The keynote will focus on the integration of NMDA-targeted drug therapy (such as ketamine) with other emerging modalities such as Transcranial Magnetic Stimulation (TMS) and Digital Therapeutics to produce synergistic therapeutic effects that will permanently alter the clinical trajectory of patients with suicidal depression, PTSD, and other debilitating neuropsychiatric conditions for which there is a great need for better treatments. Although the introduction of ketamine for these and other indications has been a medical breakthrough, intravenous ketamine alone is not sufficiently efficacious for many patients, and may not create a sufficiently durable response for many for whom it is highly efficacious. Recent data suggest that the integration of ketamine with other emerging neuromodulation, pharmacologic and Digital Therapeutics may be key to inducing improvements that are sufficiently strong and durable to allow all patients who suffer from suicidal depression and PTSD lead productive and rewarding lives.

The Sachs Forum, held annually during the JP Morgan Healthcare Conference week, brings together leaders and innovators in neuroscience to explore cutting-edge advancements in therapeutics, neurotechnology, and diagnostics. Lifesaving therapies for CNS diseases that are widely deployed today were first presented at this event. Drs. Javitt and Feifel look forward to sharing insights on the unmet needs in psychiatric care for patients with suicidal depression and PTSD and the path forward for HOPE Therapeutics.

Prof. David Feifel, MD PHD, HOPE’s newly designated Chief Medical Innovation Officer, has been a pioneer and international thought leader for advanced interventional treatment of psychiatric disorders such as depression, anxiety, PTSD and related disorders for more than three decades. Among other things, he is a co-author on a recent landmark expert consensus paper for treating depression with TMS, endorsed by three leading organizations in the field (ref). He also established the first clinical program to use subanesthetic dose ketamine infusions for neuropsychiatric disorders at UC San Diego, where he is currently Professor Emeritus of Psychiatry. His 150 peer-reviewed publications and several patents have provided global thought leadership on advanced approaches to treating psychiatric conditions, including integration of medicines like ketamine with neuromodulation, such as Transcranial Magnetic Stimulation and Digital Therapeutics.

A replay of the presentation will be available shortly after the conference on the NRx website. https://ir.nrxpharma.com/events

HOPE and NRx Key Recent Developments

Binding term sheet for $27 Million in anticipated funding for HOPE Clinic acquisitions and pharmaceutical operationsAnnounced Kadima Neuropsychiatry Institute and Dura Medical as the first planned acquisitions for its international network of interventional psychiatry clinicsInitiated filing of its NDA to the FDA for NRX-100 (IV Ketamine) for the treatment of suicidal depression and preparing to file an NDA for Accelerated Approval of NRX-101 for bipolar depression with suicidality or akathisia

Upcoming Milestones

1Q 2025 – Planned completion of NRX-100 filing with the FDA1Q 2025 – Targeted NDA filing for NRX-101 (Oral DCS/Lurasidone) for Accelerated Approval1Q 2025 – Further HOPE clinic acquisitions

About HOPE Therapeutics, Inc.

HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a development stage healthcare delivery company that intends to develop a best-in-class network of interventional psychiatry clinics to offer ketamine transcranial magnetics stimulation (TMS) and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.

About NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRx has recently initiated a New Drug Application filing for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the satisfaction of closing conditions necessary to consummate the acquisition of Kadima and Dura, and obtaining financing necessary to consummate the acquisitions. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “believe,” “intend,” “look forward,” and other similar expressions among others. These statements relate to future events or to the Company’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company’s current views with respect to future events and is subject to these and other risks, including the risk that the transactions contemplated by the LOI are not consummated, uncertainties and assumptions relating to the Company’s operations, results of operations, growth strategy, liquidity, HOPE Therapeutic’s ability to consummate the acquisitions of providers for its national network, the Company’s ability to raise adequate capital to fund such acquisitions, and the Company’s ability to spin-off HOPE Therapeutics. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

For further information:
Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-Chief Executive Officer, HOPE Therapeutics, Inc.
mduffy@nrxpharma.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaqnrxp-announce-dr-jonathan-javitt-and-dr-david-feifel-to-present-keynote-address-beyond-ketamine-monotherapy-combined-interventional-treatment-of-suicidal-depressi-302344042.html

SOURCE NRx Pharmaceuticals, Inc.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Bank Alfalah Acquires Strategic Stake in UAE Fintech Jingle Pay

Published

on

By

DUBAI, UAE, Jan. 10, 2025 /PRNewswire/ — Bank Alfalah, a leading commercial bank in Pakistan with a network of over 1,000 branches, has announced its acquisition of a 9.9% equity stake in Jingle Pay, one of the fastest growing fintechs in the MENAP region. The Bank’s fintech investment underscores its commitment to driving digital transformation and fostering financial inclusion across key markets.

Jingle Pay has redefined the fintech space with its proprietary AI-powered tech stack already processing over 2 million transactions and facilitating over $1 billion in international money transfers in 2024, saving customers over $6 million in fees. Jingle Pay was recently awarded the top global fintech for remittances into Pakistan.

Jingle Pay has solidified its position as a high-growth fintech leader in the MENAP region, supported by prestigious investors, including MoneyGram, G42-backed Applied AI, and prominent U.S. venture capital firms known for backing global fintech giants like N26 and PayPal, Jingle Pay continues to disrupt the industry. Bank Alfalah’s equity investment and appointment to Jingle Pay’s Board signal a robust partnership aimed at driving growth and innovation. This collaboration leverages Bank Alfalah’s extensive infrastructure to amplify Jingle Pay’s impact on cross-border payments and digital banking, advancing its ambitious vision for the MENAP region.

Jingle Pay provides innovative services, including multi-currency accounts, instant money transfers via the world’s first remittance marketplace, card payments, and last-mile payouts across 150+ corridors in 99+ currencies. Additionally, its Remittance-as-a-Service solution enables banks, FinTech’s, and non-financial institutions to facilitate seamless international money transfers.

Jingle Pay plans to launch its digital banking services in Pakistan in Q1 2025 as a branchless banking mobile app targeting to bring seamless and inclusive financial services to the country’s largely unbanked population. Jingle Pay will leverage Bank Alfalah’s infrastructure to bring seamless banking solutions to millions of customers. The partnership will create synergies in cross-border payments strengthened by shareholder MoneyGram.

As Pakistan’s 5th largest remittance partner, Jingle Pay plays a crucial role in driving global financial flows that contribute significantly to the country’s GDP. Establishing local presence in Pakistan will strengthen its partnership and cross-border capabilities, further cementing Jingle Pay’s position as a leader in the remittance ecosystem.

Leadership Remarks

Farooq A. Khan, Group Head – Corporate, Investment Banking and International Business of Bank Alfalah, emphasized: “This acquisition is a milestone in our journey to lead the digital banking revolution. By combining Jingle Pay’s innovative platform with Bank Alfalah’s resources, we aim to redefine cross-border financial services and deliver exceptional value to millions of users.”

Amir Fardghassemi, Founder and CEO of Jingle Pay, said: “Partnering with Bank Alfalah empowers us to scale our vision of inclusive finance. Together, we aim to enrich the digital economy and create transformative cross-border financial solutions.”

The collaboration also enhances Bank Alfalah’s role in the global Payments ecosystem, strengthening its position as a leader in cross-border financial flows and delivering unparalleled value to customers in the MENAP and beyond.

About Bank Alfalah

Bank Alfalah is a leading commercial bank in Pakistan, with over 1,000 branches across 200 cities and an international presence in the UAE, Bahrain, and Afghanistan. Its heritage and prominence extend over 25 successful years, highlighted by achievements that reflect exponential growth in the country’s financial sector.

The Bank offers various products and services to private-sector institutions and governments, including corporate and investment banking, consumer banking, securities brokerage, commercial, small and medium enterprises, agricultural, Islamic, and asset financing.

The Bank has established itself as a premier digital bank by introducing various features on its banking app, such as Alfamall, Buy Now Pay Later, and Term Deposit Receipts. It has also launched Pakistan’s first digital lifestyle branch. 

About Jingle Pay

Jingle Pay, a UAE born fintech, is the MENAP region’s leading and fastest-growing fintech, specializing in cross-border money transfers licensed by Dubai Financial Services Authority (DFSA). Jingle Pay operates in the UAE, Bahrain, and Pakistan, offering cutting-edge financial services. Backed by global financial institutions like MoneyGram, Bank Alfalah, top-tier U.S. and international venture capital firms that have backed PayPal and N26, as well as G42 backed, Applied AI.

The company provides a wide array of solutions, including Remittance-as-a-Service for financial institutions, enabling seamless global payouts across 150+ corridors and 99+ currencies. Additionally, Jingle Pay operates a B2C app for retail customers, facilitating card payments and international money transfers focused on driving financial inclusion and leveraging AI to redefine cross border payments.

CONTACT: Jingle Pay, Media@jinglepay.com, +971 4 547 7778

Photo – https://mma.prnewswire.com/media/2594862/Jingle_Pay.jpg

View original content:https://www.prnewswire.co.uk/news-releases/bank-alfalah-acquires-strategic-stake-in-uae-fintech-jingle-pay-302347236.html

Continue Reading

Technology

Better Business Bureau Serving the Tri-Counties Warns Homeowners About Donation Scams Following Southern California Fires

Published

on

By

BBB Offers Recommendations for Donating to Southern California Wildfire Requests, Warning to Beware of Click-Bait and Phishing Scams, Bogus Crowdfunding Requests

SANTA BARBARA, Calif., Jan. 9, 2025 /PRNewswire-PRWeb/ — Better Business Bureau Serving the Tri-Counties issues warning to businesses and consumers tied to donation scams following Southern California Fires. As reported, strong winds fueling a fast-moving fire in Southern California has caused more than 100,000 people to evacuate their homes. For those seeking to help those in need, BBB Wise Giving Alliance offers the following tips to give thoughtfully.

For those seeking to help those in need, BBB Wise Giving Alliance offers the following tips to give thoughtfully.

Tips for Donating to Southern California Wildfire Relief Efforts

Make Sure the Charity Is Trustworthy: Before giving, search for the charity’s report on Give.org to find out if the charity meets the BBB Standards for Charity Accountability (i.e., a BBB Accredited Charity). While disaster fundraising has not yet fully emerged for this tragedy, donors might check with the following BBB Accredited Charities to help start their selection of organizations offering help: American Red Cross, Direct Relief, GlobalGiving and Salvation Army.

Look for Specific Fire Relief Activities in Appeals: Be wary of relief appeals that have vague program descriptions and do not explain what activities your support will assist.

Watch Out for Click-Bait and Phishing Scams: Online giving scams tend to pop up after a disaster to take advantage of public sympathy. Don’t click on email, text, or social media links promising to connect you to a familiar charity. Instead, go directly to the charity’s website on your own.

Review Crowdfunding Requests: Some crowdfunding sites take precautions in carefully screening, vetting, and managing postings after a disaster or tragedy. Others might not. If unsure, review the procedures described on the site and also find out about transaction fees and other specifics.

Verify Charity Registration: About 40 of the 50 states require charities to annually register. Check with your state’s office of the attorney general or secretary of state’s office.

Understand the Phases of Disaster Relief: Most disasters go through three periods of activity: rescue, relief, and recovery. Each phase involves different activities and support. You can familiarize yourself with each phase on our Supporting Disaster Relief and Preparedness page.

Better Business Bureau Serving the Tri-Counties intends for this advice to help donors to give with confidence while avoiding questionable efforts.

For more information
To report a scam, go to BBB Scam Tracker.
To learn how to protect yourself, go to “10 Steps to Avoid Scams.”

Media Contact

Frank Tortorici, Marketing Maven, (908) 875-8908, frank@marketingmaven.com, https://marketingmaven.com/ 

View original content to download multimedia:https://www.prweb.com/releases/better-business-bureau-serving-the-tri-counties-warns-homeowners-about-donation-scams-following-southern-california-fires-302347662.html

SOURCE Better Business Bureau

Continue Reading

Technology

Pollo AI Launches Consistent Character Video to Maintain Consistency of Characters, Objects, or Scenes in Generated Videos

Published

on

By

SINGAPORE, Jan. 9, 2025 /PRNewswire/ — Pollo AI  continues to raise the bar in AI video generation with the addition of its latest feature: Consistent Character Video, which can transform still images into high quality AI videos, while maintaining consistency of characters, objects, or scenes throughout every frame.

Users can upload one or up to three images of a subject to the tool – it could be a person’s face, for example, or image(s) of an inanimate object, like an appliance or piece of clothing, or image(s) of specific scenes. The AI video generator will then use the image(s) as the reference point(s) when generating its video content, ensuring that the original visuals are accurately and consistently portrayed.

This way, users can make multiple videos while keeping the same consistent subjects. They can make themselves the star of numerous clips, for example, or incorporate real-life items into their video creations. While other elements of the videos may change, the core subjects you choose will always remain consistent.

The uses for this are numerous. Brands, for example, could upload images of their latest products and then make various AI-generated videos featuring those products in a range of settings and scenarios. Or creators could make entire feature-length films by generating multiple short-form AI videos with the same consistent subjects in different scenes.

You could even upload an image of a famous landmark or monument, and instruct the tool to use that throughout your video creations. This makes it so much easier to create sequences or series of videos with the same consistent background, environment, or setting – a feat that many AI video generators have historically struggled with.

It’s a huge leap forward for AI video technology. Before the Consistent Character Video Generator, many users had expressed frustration when it came to trying to keep the same characters and subjects in multiple AI-generated videos. But with this new tool, that challenge has been solved.

What’s more, the Consistent Character Video Generator is backed up by Pollo AI’s advanced algorithms and powerful technology. Thanks to that, it’s able to make some of the most visually impressive AI videos, with cinematic levels of quality, fluid motion, realistic physics, and other desirable characteristics.

Plus, just like other AI videos generated with Pollo AI, the user has total control over various aspects, such as the aspect ratio, the length of the video, the resolution, and the camera movement. With this bold new addition, Pollo AI continues to assert itself as one of the leading and most innovative names in the AI video sphere.

View original content:https://www.prnewswire.com/news-releases/pollo-ai-launches-consistent-character-video-to-maintain-consistency-of-characters-objects-or-scenes-in-generated-videos-302347735.html

SOURCE Pollo AI

Continue Reading

Trending